COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804


Print ISSN:-2581-5555

Online ISSN:-2456-9542

CODEN : IIJCDU

Current Issue

Year 2020

Volume: 5 , Issue: 1

Article Access statistics

Viewed: 227

Emailed: 0

PDF Downloaded: 82

IP International Journal of Comprehensive and Advanced Pharmacology


Comparative study of control of hyperglycemia and dyslipidemia between two treatment- groups of diabetic patient (Metformin Monotherapy and Metformin + Glimepiride Combination)


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Subhradipta Bhattacharyya*, Brijesh Mukherjee

Volume : 4, Issue : 3, Year : 2019

Article Page : 91-95


Suggest article by email

Abstract

Aim: The aim of the study is to examine whether the combination of metformin+ glimepiride is superior to metformin mono therapy to treat the newly diagnosed type 2 DM patients to control the HbA1C and dyslipidaemia in terms of LDL, total cholesterol, TG etc.
Materials and Methods: A Prospective randomised study with four groups. The control comprises of 60 healthy volunteers. 120 newly diagnosed type 2 DM cases (Group 1) were enrolled in the study. These 120 patients were randomised into two groups; Group 2 with 60 patients to receive Metformin and Group 3 with 60 patients to receive Metformin + glimepiride combination. Both the Group 2 and Group 3 have received the same hypolipidemic and antihypertensive drugs.
Results: After about 4 years of treatment, in Group 2 and Group 3, FPG, HbA1C% and lipid profile were improved significantly (p< 0 P=0.85)>
Conclusion: Metformin and Glimepiride combination therapy improves HbA1c, LDL-C, HDL-C more effectively. However, Group 2 patients had shown better AIP than Group 3 patients.

Keywords: Monotherapy, Combination therapy, Glycaemic control, Dyslipidemia, Atherogenesis.

Doi : 10.18231/j.ijcaap.2019.019

How to cite : Bhattacharyya S, Mukherjee B, Comparative study of control of hyperglycemia and dyslipidemia between two treatment- groups of diabetic patient (Metformin Monotherapy and Metformin + Glimepiride Combination). IP Int J Compr Adv Pharmacol 2019;4(3):91-95

Copyright © 2019 by author(s) and IP Int J Compr Adv Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)